Product Description: Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator[1].
Applications: Cancer-Kinase/protease
Formula: C28H24ClF3N4O6S
Citations: Adv Sci (Weinh). 2022 Nov 29;e2203718./Am J Cancer Res. 2017 Dec 1;7(12):2503-2514. /Am J Transl Res. 2021 Jul 15;13(7):7508-7523./Autophagy. 2021 May 7;1-13./Bone Res. 2024 Apr 10;12(1):24./Fundam Clin Pharmacol. 2020 Oct 4. /Int J Biochem Cell Biol. 2020 Sep;126:105820./Int J Mol Sci. 2022, 23(19), 11092./J Enzyme Inhib Med Chem. 2020 Dec;35(1):344-353./Math Biosci Eng. 2019 Jul 8;16(6):6319-6334./NPJ Syst Biol Appl. 2019 Aug 16;5:29. /Oncotarget. 2017 Oct 6;8(52):90185-90196. /PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. /Saudi Pharm J. 2023 Jun 1./ACS Appl Mater Interfaces. 2017 Apr 12;9(14):12195-12202./ACS Chem Biol. 2016 Apr 15;11(4):992-1000./ACS Chem Biol. 2017 Jan 20;12(1):282-290. /ACS Nano. 2023 Nov 15./Acta Pharm Sin B. 2023 Mar 31./Acta Pharm Sin B. 2023 Oct;13(10):4253-4272./Acta Pharmacol Sin. 2021 Jan;42(1):108-114./Adv Healthc Mater. 2023 Apr 14;e2203120./Adv Sci (Weinh). 2021 Jan 29;8(6):2002831./Adv Sci (Weinh). 2022 May;9(15):e2105894./Adv Sci (Weinh). 2023 Jul 23;e2302640./Adv Sci (Weinh). 2023 Jun 17;e2206798./Adv Sci (Weinh). 2024 Jul 9:e2402327./Advances in Parkinsons Disease. 2021, 10, 1-13./Am J Digest Dis. 2015;2(2):95-99./Am J Transl Res. 2020;12(3):825-836./Am J Transl Res. 2023 Feb 28;15(2):896-913./Biochem Bioph Res Co. 2020 Sep 3;529(4):1086-1093./Biochem Biophys Res Commun. 13 January 2022./Biochem Biophys Res Commun. 2023 Jun 10./Biochem Pharmacol. 2023 Apr 18;115554./Biochem Pharmacol. 2023 May 15;115593./Biochem Pharmacol. 2019 Nov;169:113612. /Biol Direct. 2024 Nov 11;19(1):110./Biology (Basel). 2023 Oct 16, 12(10), 1337./Biomaterials. 16 September 2022./Biomaterials. 17 March 2022./Biomed Pharmacother. 2016 Dec 6;86:27-31./Biomed Pharmacother. 2020 Jun;126:109862./Biomed Pharmacother. September 2022, 113540./Biomed Res Int. 2019 Nov 28;2019:2410845./bioRxiv. 2021 Jan 25./BMC Complement Med Ther. 2023 Jun 26;23(1):210./BMC Cancer. 2019 Aug 1;19(1):760. /Br J Cancer. 2017 Sep 26;117(7):974-983./Br J Pharmacol. 2021 Feb;178(3):636-653./Braz J Med Biol Res. 2021 May 31;54(9):e10390./Can J Gastroenterol Hepatol. 2022./Cancer Cell Int. 2019 Aug 27;19:222./Cancer Discov. 2019 Dec;9(12):1686-1695./Cancer Discov. 2021 Oct;11(10):2544-2563./Cancer Lett. 20 October 2021./Cancer Lett. 2019 May 28;450:132-143./Cancer Lett. 2021 Jul 30;S0304-3835(21)00382-7./Cancers (Basel). 2023 Nov 3, 15(21), 5280./Cancers. 2020 Jun 30;12(7):1737./Cell Biol Toxicol. 2023 Mar 31./Cell Biol Toxicol. 2024 Nov 26;40(1):104./Cell Commun Signal. 2024 Aug 7;22(1):391./Cell Death Differ. 2021 Apr;28(4):1222-1236./Cell Death Dis. 2021 Jul 9;12(7):691./Cell Death Dis. 2022 Feb 4;13(2):118./Cell Death Dis. 2023 Jan 12;14(1):22./Cell Death Dis. 2024 Jan 18;15(1):66./Cell Death Dis. 2024 Jun 5;15(6):395./Cell Death Dis. 2019 Apr 15;10(5):331./Cell Death Discov. 2022 Aug 17;8(1):365./Cell Death Discov. 2023 Sep 30;9(1):362./Cell Discov. 2022 May 3;8(1):40./Cell Metab. 2021 Sep 8;S1550-4131(21)00375-2./Cell Rep Methods. 2023 Oct 23;3(10):100599./Cell Rep. 2023 Dec 12;42(12):113563./Cell Rep. 2024 Nov 27;43(12):114996./Cell Rep. 2024 Oct 24;43(11):114885./Cell Signal. 2024 Jun 27:111278./Chem Cent J. 2017 Jan 3;11:1./Chemical Engineering and Applied Chemistry Institute of Biomaterials and Biomedical Engineering, University of Toronto. 2019 Aug./Chemosphere. 2022 Sep 7;136354./Chin J Nat Med. 2022 Mar;20(3):202-209./Chin Med. 2024 Aug 24;19(1):113./Clin Cancer Res. 2024 Jul 25./Clin Med Insights Oncol. 2024 Oct 16:18:11795549241285387./Clin Sci. 2021 Jul 20;CS20210571./Clin Sci. 2024 Sep 18;138(18):1131-1150./Clin Transl Med. 2023 Jun;13(6):e1300./Commun Biol. 2024 Oct 8;7(1):1279./Comput Biol Med. 2024 Feb, 169, 107975./Dig Liver Dis. 2023 May 23;S1590-8658(23)00618-7./Discov Oncol. 2023 May 27;14(1):83./Diseases. 2023 Oct 23;11(4):147./Drug Deliv. 2023 Dec;30(1):2174209./Drug Des Devel Ther. 2024 Sep 12:18:4065-4088./Endocr J. 2017 Nov 29;64(11):1115-1123./Endocrinology. 2023 Sep 13;bqad135./Environ Toxicol. 2021 Oct 18./Eur J Med Chem. 2024 Mar 5:267:116209./Eur J Pharmacol. 2021 Jun 1;174217./Evid Based Complement Alternat Med. 15 Oct 2022./Exp Cell Res. 2020 Aug 1;393(1):112054./Exp Cell Res. 2021 Jul 29;112755./Exp Cell Res. 2022 May 25;113223./Exp Hematol Oncol. 2016 Jul 29;5:22. /Free Radic Biol Med. 2020 Nov 20;160:303-318./Free Radic Biol Med. 2021 Feb 1;163:141-152./Front Biosci (Landmark Ed). 2024 Jan 19, 29(1), 3./Front Oncol. 2021 Jul 13;11:704042./Front Oncol. 2022 Jul 8;12:939605./Front Pharmacol. 2022 Jul 11;13:930958./Front Pharmacol. 2024 Apr 5./Genes Dis. 2023 Sep 16, 101114./Gut Microbes. 2024 Jan-Dec;16(1):2410474./Heliyon. 2024 Jan 13, e24461./Heliyon. 2024 May 31./Hepatol Commun. 2024 Mar 29;8(4):e0405./Immunology. 2023 Apr 17./Int Immunopharmacol. 2024 Sep 30;143(Pt 1):113226./Int J Biol Sci. 2018 Apr 25;14(5):577-585./Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81./Int J Clin Exp Pathol. 2017;10(3):3033-3042./Int J Med Sci. 2021 Jan 29;18(6):1456-1464./Int J Mol Sci. 2023 Dec 23, 25(1), 269./Int J Nanomedicine. 2024 Dec 3:19:12975-12998./Integr Biol (Camb). 2018 Oct 15;10(10):646-657./iScience. 2023 May 29, 106994./J Cancer. 2021 Jan 1;12(2):343-357./J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Sep 1;1061-1062:220-224./J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Mar 26:1237:124100./J Clin Transl Hepatol. 2025 Jan 28;13(1):15-24./J Ethnopharmacol. 2021 Aug 4;280:114480./J Exp Clin Cancer Res. 2022 Mar 30;41(1):116./J Exp Clin Cancer Res. 2023 Jan 6;42(1):6./J Exp Clin Cancer Res. 2018 Nov 29;37(1):295./J Extracell Vesicles. 2024 Jul;13(7):e12468./J Hepatocell Carcinoma. 2023 Apr 11;10:611-629./J Immunother Cancer. 2022 Aug;10(8):e004006./J Med Chem. 2019 Nov 14;62(21):9593-9599. /J Mol Med (Berl). 2022 Feb 5./J Pharmacol Exp Ther. 2017 Aug;362(2):219-229. /J Transl Med. 2022 Jun 6;20(1):255./J Transl Med. 2023 Jan 9;21(1):9./J Transl Med. 2024 Aug 28;22(1):792./Journal of Pharmaceutical Research International. 33(47B): 274-279, 2021./Kaohsiung J Med Sci. 16 November 2021./Lab Chip. 2018 Nov 6;18(22):3379-3392./Med Oncol. 2022 Sep 29;39(12):221./Mol Cancer Ther. 2020 May;19(5):1197-1209./Mol Carcinog. 2023 May 22./Mol Cell Probes. 2022 Nov 25;101877./Mol Cell. 2023 Dec 7;83(23):4334-4351.e7./Mol Oncol. 19 August 2022./Molecules. 2018 Mar 23;23(4). pii: E736./Nat Cancer. 2024 May 30./Nat Commun. 2022 Mar 18;13(1):1478./Nat Commun. 2024 Sep 10;15(1):7923./Nat Commun. 2025 Jan 2;16(1):87./Neuropharmacology. 2019 Jan 30;148:347-357./Oncogene. 2021 Jul 10./Oncogene. 2022 Feb 10./Oncol Rep. 2017 Jan;37(1):273-280. /Oncol Rep. 2018 Sep;40(3):1525-1532. /Oncol Rep. 2020 Dec 9./Oncotarget. 2017 May 2;8(18):29771-29784./Pakistan J Zool. 2021 May./Patent. US20180263995A1./Patent. US20220305013A1./Personalized Medicine Universe. 2019 May. /Pharmacol Res. 2021 Dec 29;106050./Pharmacol Res. 2022 Jun;180:106244./Phytochemistry. 2021 Jun 1;189:112816./Phytomedicine. 2023 Nov 25, 155225./Phytomedicine. 8 September 2021, 153740./Prostate. 2018 Apr;78(5):343-352./Redox Biol. 2022: 102564./Redox Biol. 2024 Mar 28:72:103131./Redox Biol. 2024 Nov 5:78:103419./Res Sq. 2024 Sep 16./Research Square Preprint. 2021 Aug./Research Square Preprint. 2022 Jan./Research Square Preprint. 2022 Jul./Research Square Preprint. 2022 May./Research Square Preprint. 2023 Mar 29./Research Square Preprint. 2023 Nov 11./Research Square Print. 2023 Feb 20./Research Square Print. October 3rd, 2022./RSC Adv. 2018 8:6425-6435./Sci Rep. 2017 Sep 8;7(1):11006. /Sci Rep. 2022 Apr 21;12(1):6120./Sci Transl Med. 2018 Jul 18;10(450):eaaq1093./Sens Actuators B Chem. 2024 Nov 1./Signal Transduct Target Ther. 2023 Sep 14;8(1):348./SSRN. 2023 Apr 24./SSRN. 2023 Jan 27./SSRN. 2024 Oct 16./Stem Cell Res Ther. 2023 Apr 1;14(1):58./Theranostics. 2020 Aug 21;10(23):10498-10512. /Toxicol In Vitro. 2021 Jul 20;76:105226./Toxicology. 2023 Mar 2;153475./Transl Oncol. 2024 Nov 27:51:102214./Virol Sin. 2023 Jul 3;S1995-820X(23)00079-2./World J Gastroenterol. 2021 Jul 28;27(28):4667-4686.
References: [1]Wilhelm SM, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109./[2]Huynh H, et al. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med. 2009 Aug;13(8B):2673-83./[3]El-Ashmawy NE, et al. Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor. Clin Exp Med. 2016 Apr 16./[4]Zhu W, et al. Combination of sorafenib and Valproic acid synergistically induces cell apoptosis and inhibits hepatocellular carcinoma growth via down-regulating Notch3 and pAkt. Am J Cancer Res. 2017 Dec 1;7(12):2503-2514.
CAS Number: 475207-59-1
Molecular Weight: 637.03
Compound Purity: 99.91
Research Area: Cancer
Solubility: DMSO : ≥ 31 mg/mL
Target: Apoptosis;Autophagy;Ferroptosis;FLT3;Raf;VEGFR
English
Deutsch
